

Structured products are not collective investment schemes within the meaning of the Collective Investment Schemes Act (CISA) and are not subject to approval or supervision by the Swiss Financial Market Supervisory Authority FINMA. Investors also bear an issuer risk.



ZKB Basket «Healthcare Diagnostics & Technology»

November 2023

Innovations ensure early detection of diseases and reduce healthcare costs

Endoscopes and diagnostic test systems improve the productivity and efficiency of medical diagnosis and treatment. They are already making a significant contribution to the early detection of diseases and to reduce healthcare costs. Increasing market penetration and strong innovation in endoscopy and diagnostics should reinforce these positive effects in the future.

Endoscopes are used in minimally invasive medical procedures. Diagnostic tests are used to detect and quantify viruses, bacteria, antigens, toxic substances and a wide range of molecules and cells.

In both endoscopy and diagnostics, products have been developed in recent years that allow patients to be examined and treated faster, earlier and more gently. Both technologies are therefore helping to curb the expected rise in healthcare costs as a result of demographic change. From today's perspective, the pace of innovation in both sectors is likely to remain above average.

All the companies included in the basket are leaders in endoscopy or diagnostics, either in terms of the products and services offered or as part of the upstream value chain. The underlying stocks are selected from the sub-sectors healthcare diagnostics and healthcare technology, and are diversified across regions. The equities are dynamically selected by ZKB Asset Management.

The basket in detail

The 25 selected stocks are included in the baskets with equal weighting on the initial fixing date. The diversification of the investments across different geographical regions and innovations ensures a certain degree of risk diversification.

Dynamic Tracker Certificate on the ZKB Basket «Healthcare Diagnostics & Technology»

- Focus on the sub-sectors healthcare diagnostics and healthcare technology
- Dynamic stock selection by ZKB Asset Management

Key Data

ZKB Dynamic Tracker Certificate

| | |
|---------------------|---|
| Underlying | Equity Basket «Healthcare Diagnostics & Technology» |
| Currency | CHF |
| Trading unit | 1 Structured Product |
| Issue Price | CHF 100.00 |
| Subscription period | 17. November 2023, 4 p.m. |
| Initial Fixing Date | 20. November 2023 |
| Issue Date | 27. November 2023 |
| Maturity | open-end |
| Management Fee | 0.75% p.a. |
| ISIN | CH1218244486 |
| Symbol | HEDITZ |

ZKB Equity Basket «Healthcare Diagnostics & Technology»

| Stock Selection | Bloomberg Ticker |
|-------------------------------|------------------|
| Asahi Intecc Co Ltd. | 7747 JT |
| Biomerieux | BIM FP |
| Boston Scientific Corp | BSX UN |
| Canon Inc. | 7751 JT |
| Carl Zeiss Meditec AG | AFX GY |
| Danaher Corp | DHR UN |
| Diasorin SpA | DIA IM |
| Eurofins Scientific | ERF FP |
| Fujifilm Holdings Corp | 4901 JT |
| Halma Plc | HLMA LN |
| Hoya Corp | 7741 JT |
| Intuitive Surgical Inc. | ISRG UW |
| Medtronic Plc | MDT UN |
| Merck KGaA | MRK GY |
| Merit Medical Systems Inc. | MMSI UW |
| Olympus Corp | 7733 JT |
| Qiagen N.V. | QIA GY |
| Quest Diagnostics Inc. | DGX UN |
| Roper Technologies Inc. | ROP UN |
| Smith & Nephew Plc | SN/ LN |
| Sony Group Corp | 6758 JT |
| Stryker Corp | SYK UN |
| Sysmex Corp | 6869 JT |
| Thermo Fisher Scientific Inc. | TMO UN |
| Wuxi Aptec Co Ltd.-H | 2359 HK |

Overview of the selected stocks

Asahi Intecc Co Ltd.

The Japanese company manufactures miniature coils for endoscopes, among other products.

Biomerieux

Based near Lyon, the company develops and manufactures tests, instruments and software for immunoassays, microbial and molecular testing.

Boston Scientific Corporation

The US company focuses on minimally invasive medical devices, including those used in endoscopy.

Canon Inc.

The Japanese company's medical division develops AI-based image processing systems that are used in conjunction with endoscopes.

Carl Zeiss Meditec AG

The company based in Jena, Germany specialises in ophthalmology and is developing a surgical robot for minimally invasive head surgery.

Danaher Corporation

The US company's diagnostics division offers a range of reagents, consumables, software and services that are important for diagnostic testing.

Diasorin SpA

Based in northern Italy, Diasorin specialises in immuno and molecular diagnostics, offering tests and test evaluation equipment.

Eurofins Scientific

Based in Luxembourg, Eurofins Scientific operates an international chain of laboratories providing diagnostic testing services.

Fujifilm Holdings Corporation

The Japanese company is a global leader in the field of image processing systems. They are used, among other things, in the endoscopes of Pentax Corp, which belongs to the group.

Halma Plc

In its medical technology division, the UK-based company develops components for endoscopes as well as for in-vitro diagnostic systems.

Hoya Corporation

The Tokyo-based company specialises in optoelectronic products and offers, among other things, micro-optics systems for endoscopes.

Intuitive Surgical Inc.

The company is a leader in surgical robots, which are typically paired with endoscopic components.

Medtronic Plc

The US medical technology company offers, among other things, endoscopes.

Merck KGaA

The globally active pharmaceutical and specialty chemicals group from Darmstadt in Germany offers, among other products, reagents and diagnostic test kits.

Merit Medical Systems Inc.

Based in the US state of Utah, the company offers, among other things, a range of instruments that are mounted on endoscopes.

Olympus Corporation

The Japanese company is the world market leader in the field of high-end endoscopes.

Qiagen N.V.

The company, which is registered in Venlo in the Netherlands, but whose most important production sites are in Germany and the US, concentrates on the development and production of diagnostic tests as well as bioinformatics solutions for the evaluation of test results.

Quest Diagnostics Inc.

Quest Diagnostics Inc. is based in the US state of New Jersey and operates a chain of laboratories mainly in the United States. The laboratories perform evaluations of a wide range of diagnostic tests.

Roper Technologies Inc.

This company, which actually focuses on industrial software and networking solutions, also offers products in the areas of clinical and laboratory management systems.

Smith & Nephew Plc

The British medical technology company offers, among other things, surgical robots that are used in the knee and hip area and have endoscopic components.

Sony Group Corporation

In cooperation with Olympus, the Japanese company develops image processing systems for endoscopes that support doctors in the detection of small lesions and tumours.

Stryker Corporation

The company from the US state of Michigan specialises in medical technology and offers, among other things, endoscopes.

Sysmex Corporation

The Japanese company produces reagents and equipment for diagnostic tests, with a focus on blood analysis. In 2021, it launched its own surgical robot, which includes endoscopic components.

Thermo Fisher Scientific Inc.

Thermo Fisher Scientific offers a wide range of products and services, including reagents for diagnostic tests, serving companies in the pharmaceutical and biotech industry, academic research and hospitals.

Wuxi Aptec Co. Ltd.-H

Among many other products and services for the pharmaceutical industry, the Chinese company develops and sells a wide range of reagents used in diagnostic tests as well as the associated analysis and evaluation systems.

Contact

Zürcher Kantonalbank, Postfach, 8010 Zürich

Sales Structured Products

Phone: +41 (0)44 293 66 65 / E-Mail: derivate@zkb.ch

www.zkb.ch/strukturierteprodukte

Legal notice

This document is for promotional purposes. Due to legal, regulatory or fiscal provisions, products and services may be subject to restrictions based on residence or domicile, nationality or customer segmentation. Therefore, it cannot be excluded that certain products and services may not be suitable or available for all persons. This document has been prepared by Zürcher Kantonalbank with due diligence. However, it offers no guarantee for the accuracy and completeness of the information contained therein and disclaims any liability arising from the use of the document. This document is neither an offer to conclude a contract nor an invitation to submit an offer for products and services. It does not constitute an offer or a recommendation to acquire, hold or sell financial instruments. Every investment is associated with risks, in particular those of fluctuations in value and earnings and possibly exchange rates. For an assessment of the specific risks of investments, it is recommended to consult the risk information provided by the bank (e.g. risk brochure, prospectuses, basic information sheet or other product documentation). This document has not been prepared by the "Financial Analysis" department within the meaning of the "Guidelines to Ensure the Independence of Financial Analysis" issued by the Swiss Bankers Association and is therefore not subject to these guidelines. However, companies of the Zürcher Kantonalbank Group may publish financial analyses in relation to the Underlying. Such activities may lead to conflicts of interest both among the relevant companies of the Zürcher Kantonalbank Group and between these companies and the investors. This document contains general information and does not take into account personal investment objectives or the financial situation or particular needs of any specific recipient. The recipient should carefully review the information for compatibility with his or her personal circumstances before making an investment decision. For the assessment of legal, regulatory, tax and other implications, the recipient is advised to seek professional advice. This document does not constitute a (base) prospectus, final terms or a base information sheet. The base prospectus, the final terms and any base information sheet are available free of charge from Zürcher Kantonalbank, Bahnhofstrasse 9, 8001 Zurich, VRIE department, as well as from www.zkb.ch/finanzinformationen. The structured products mentioned in this document are subject in particular to the selling restrictions set out in the issuance program (EEA, U.S.A. / U.S. persons, United Kingdom, Guernsey). In particular, the structured products mentioned in this document are not available to U.S. persons under the relevant regulations. We draw your attention to the fact that telephone calls to trading and sales units of Zürcher Kantonalbank are recorded. With your call, you tacitly consent to the recording.